Evaluation of Safety and Efficacy of the Apollo™ System for Treatment of Wrinkles and Rhytides
1 other identifier
interventional
37
2 countries
2
Brief Summary
Non-invasive, energy-based, aesthetic treatments are becoming increasingly popular among female and male patients of all ages. Different technologies are presently available to rejuvenate skin, including therapeutic ultrasound, lasers and intense pulsed light (IPL), however radiofrequency has emerged as the most effective and versatile modality for the broadest range of body and facial treatments, including non-invasive wrinkle treatment. The apollo™ system is an RF system, based on the TriPollar™ technology. The technology is based on three or more electrodes designed to deliver RF current focused into the skin, thus generating heat in the dermal layer. Selective and focused electro-heating of the skin is intended to stimulate collagen remodeling in the dermal layer resulting in non invasive wrinkle treatment. The apollo™ system is intended for use in dermatologic and general surgical procedures for non invasive treatment of facial wrinkles and rhytides. This study was designed in order to evaluate the safety and efficacy of the Apollo™ System for facial wrinkles and rhytides treatments.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2011
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 25, 2011
CompletedFirst Posted
Study publicly available on registry
January 26, 2011
CompletedStudy Start
First participant enrolled
March 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2011
CompletedMay 17, 2013
November 1, 2011
6 months
January 25, 2011
May 16, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the safety of the apollo™ system for wrinkles and rhytides treatment.
The safety of using the apollo™ system for wrinkles and rhytides treatment will be established by physician's assessment/observation of adverse events.
5 months
Secondary Outcomes (1)
• To evaluate the efficacy of the apollo™ system for wrinkles and rhytides treatment.
5 months
Study Arms (1)
apollo
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Subject read, understood and signed the Consent Form
- Healthy female/male aged 35 65 years,
- Fitzpatrick wrinkle classification score 4 and above
- Subject is capable of reading, understanding and following instructions of the procedure to be applied.
- Subject is able and willing to comply with the treatment and follow-up schedule.
You may not qualify if:
- Subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past.
- Subject has metal or other implants in the treatment area (Not including dental fillings, implants and crowns).
- Subject has current or history of cancer, especially skin cancer or premalignant moles or is undergoing any form of treatment for active cancer.
- Subject has severe concurrent conditions such as epilepsy, lupus or cardiac disorders.
- Subject has poorly controlled endocrine disorders such as diabetes.
- Subject is female who is pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago.
- Subject has an impaired immune system due to immunosuppressive diseases such as HIV or AIDS, or use of immunosuppressive medications.
- Subject has a condition that could be negatively affected by heat, including any history of diseases stimulated by heat, such as recurrent Herpes Simplex (in the treatment area).
- Subject has diminished or exaggerated perception of temperature changes.
- Subject has significant concurrent skin conditions affecting areas to be treated such as sores, hemorrhages or risk of hemorrhages, septic conditions, psoriasis, eczema and rash as well as very dry and fragile skin.
- Subject has history of collagen disorders, keloid formation and abnormal wound healing.
- Subject has had previous invasive/ablative procedures in the areas to be treated within 3 months prior to initial treatment or plans on such treatment during the course of the study, or before complete healing has occurred.
- Subject has had Botox injections in the treatment area within 6 months prior to initial treatment
- Subject has had natural fillers within 9 months prior to initial treatment
- Subject has synthetic fillers or gold/plastic threads in the treatment area.
- +6 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pollogenlead
Study Sites (2)
Steven D. Shapiro MD
Palm Beach Gardens, Florida, 33410, United States
Kaplan Medical center
Rehovot, 76610, Israel
Study Officials
- STUDY DIRECTOR
Mira Barki, Dr.
Pollogen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 25, 2011
First Posted
January 26, 2011
Study Start
March 1, 2011
Primary Completion
September 1, 2011
Study Completion
September 1, 2011
Last Updated
May 17, 2013
Record last verified: 2011-11